Current hypertension reportsDec 1, 2025

Blood Pressure Lowering by SGLT2 Inhibitors and GLP-1 Receptor Agonists

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 20, 2026

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) lower office systolic blood pressure by 2.5-4.0 mmHg.

SGLT2-i also reduce 24-hour ambulatory blood pressure by 3.8 mmHg.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show modest reductions in systolic blood pressure ranging from 1.8 to 5.1 mmHg.
Tirzepatide, a GLP-1RA, demonstrates greater efficacy with reductions of approximately 10.6 mmHg in certain populations.
Both SGLT2-i and GLP-1RAs are associated with cardio-renal benefits and favorable safety profiles.
SGLT2-i have more consistent blood pressure-lowering effects than GLP-1RAs, potentially due to their diuretic-like action.

Simplified

PURPOSE OF REVIEW: Hypertension is the leading modifiable risk factor for cardiovascular disease. Despite multiple antihypertensive therapies, blood pressure (BP) control remains suboptimal in many individuals with persistent cardiovascular risk. This review evaluates the antihypertensive potential of sodium-glucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), particularly in patients with comorbid diabetes, HF, CKD or resistant hypertension.

RECENT FINDINGS: SGLT2-i consistently lower office SBP/DBP (2.5-4.0/1.5-2.0 mmHg) and 24-hour ambulatory BP (3.8/1.8 mmHg). GLP-1RAs show modest SBP reductions (1.8-5.1 mmHg) and minimal DBP effects (~ 0.5 mmHg), though tirzepatide shows greater efficacy (~ 10.6 mmHg) in select populations. Both classes have demonstrated cardio-renal benefits, favorable safety profiles, and reduced polypharmacy. SGLT2-i exert more consistent BP-lowering effects than GLP-1RA, largely due to their diuretic-like action. While not first-line therapies, both drug classes show promise as adjuncts in high-risk populations. Future research should further define their role in comprehensive hypertension management.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declarations. Competing Interests: The authors declare no competing interests.

PubMed

Blood Pressure Lowering by SGLT2 Inhibitors and GLP-1 Receptor Agonists

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief